Skip to content

Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes

Connecting the Dots: An RCT Integrating Standardized ASD Screening, High-Quality Treatment, and Long-Term Outcomes

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03333629
Enrollment
2087
Registered
2017-11-07
Start date
2017-11-29
Completion date
2024-06-30
Last updated
2024-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism Spectrum Disorder

Keywords

Autistic Disorder, Early Detection, Early Intervention

Brief summary

Autism spectrum disorder (ASD) is defined by impaired social engagement and social communication, and repetitive, restricted, or stereotyped behaviors and interests. The average age of diagnosis in the US is after the fourth birthday. However, children who start ASD-specific early intervention have better outcomes than children start later. The current study will address a gap identified by the US Prevention Services Task Force, namely that children detected through screening respond positively to early intervention. This study will directly relate early detection strategies to early intervention, and measure the impact of age of intervention onset on outcomes when children are entering kindergarten. Local pediatric providers will be randomized to provide either usual care, or to an experimental condition in which autism early detection strategies are enhanced through the addition of specific procedures. Across all sites, 8,000 children will be recruited through their participating pediatric practice. Qualifying children will receive up to one year of early intensive behavioral intervention, after getting an ASD diagnosis. Primary outcome measures will include children's cognitive functioning and ASD symptom severity, which will be measured at multiple time points. The investigators predict that this study will inform early detection strategies which will result in improving children's social and cognitive functioning, mitigating lifespan disability, reducing societal costs, and improving personal well-being and productivity of individuals with ASD.

Detailed description

Autism spectrum disorder (ASD) is a serious neurodevelopmental disorder defined by impaired social engagement and social communication, in addition to the presence of repetitive, restricted, or stereotyped behaviors and interests. Although many cases of ASD can be detected when children are less than two years old, the average age of diagnosis in the US is still after the fourth birthday. However, evidence demonstrates that children who start ASD-specific early intervention have better outcomes than children who do not start treatment until later ages. In 2006 and 2007, American Academy of Pediatrics recommended three early detection approaches to improve identification of children at risk for ASD: ongoing developmental surveillance at every well-child check-up, routine broad developmental screening at three infant/toddler ages, and ASD-specific screening at two toddler ages. When these early detection strategies are used with all children attending well-child check-ups, the age of ASD detection is lower, and children who are diagnosed have the opportunity to start ASD-specific early intervention at younger ages than if they had not been detected. Yet in 2016, the US Preventive Services Task Force (USPSTF) indicated that current evidence is insufficient to recommend universal ASD screening, given the lack of experimental studies demonstrating positive outcomes for treated children that are detected through screening. The current study will address this gap. This study will directly relate early detection strategies to early intervention, and measure the impact of age of intervention onset on outcomes when children are entering kindergarten. The study will be conducted by investigators from three sites: Drexel University; the University of California, Davis; and the University of Connecticut. Local pediatric providers will be enrolled in the study, and their practices will be randomized to provide either usual care, or to an experimental condition in which autism early detection strategies are enhanced through the addition of specific procedures. Children attending well-child visits at participating practices will then be enrolled. Across all sites, 8,000 children will be recruited through their participating pediatric practice. As part of the study, qualifying children will receive up to one year of early intensive behavioral intervention, using an evidence-based manualized treatment. Primary outcome measures will include children's cognitive functioning and ASD symptom severity, which will be measured at multiple time points. Exploratory outcomes will include children's adaptive functioning, kindergarten readiness, and social reciprocity, as measured by experimental eye tracking and parent-child interaction ratings. This study also will examine the impact of the screening intervention on physician attitudes and on parent empowerment and stress. Finally, investigators will examine potential moderators of outcomes, to determine whether initial symptom severity, cognitive ability, or socioeconomic status affects children's long-term outcomes. The investigators predict that this study will inform early detection strategies which will result in improving children's social and cognitive functioning, mitigating lifespan disability, reducing societal costs, and improving personal well-being and productivity of individuals with ASD.

Interventions

BEHAVIORALEnhanced early detection

standardized screening

Sponsors

University of California, Davis
CollaboratorOTHER
University of Connecticut
CollaboratorOTHER
Drexel University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
16 Months to 58 Months
Healthy volunteers
No

Inclusion criteria

* child attended 18 m visiting at participating pediatric practice * legal guardian is fluent in English or Spanish

Exclusion criteria

* child has severe sensory or motor deficit that precludes completing standardized evaluation

Design outcomes

Primary

MeasureTime frameDescription
Change in ASD Symptom SeverityChange from pre-treatment to immediately post-treatment; 10 minutesASD symptom severity will be measured with the Brief Observation of Social Communication Change (BOSCC)
Change in Cognitive FunctioningChange from pre-treatment to immediately post-treatment; 60 minutesCognitive functioning will be measured by the Mullen Scales of Early Learning (MSEL).

Secondary

MeasureTime frameDescription
Kindergarten Readiness60 m; 45 minutesDevelopmental Indicators for the Assessment of Learning-4
Social EngagementImmediately post-treatment, 48 m, 60 m; 15 minutesEye tracking paradigms will assess aspects of social engagement (i.e., social orienting, motivation, and cognition)
Long-term change in Cognitive Functioning48 m, 60 m; 60 minutesCognitive functioning will be measured by the Mullen Scales of Early Learning (MSEL)
Adaptive FunctioningImmediately post-treatment, 48 m, 60 m; 45 minutesVineland Adaptive Behavior Scales-3
ASD symptoms - secondary measure2Immediately post-treatment, 48 m, 60 m; 20 minutesPDD Behavior Inventory
ASD symptoms - secondary measure348 m, 60 m; 10 minutesBOSCC
Long-term change in Cognitive Functioning (alternative)48 m, 60 m; 60 minutesand for children who reach ceiling on the MSEL, we will use the Differential Differential Abilities Scales-II (DAS-II) will be used for children too advanced for Outcome 7
Parent-Child Social EngagementImmediately post-treatment, 48 m, 60 m; 15 minutesParent-child social engagement will be measured with the Joint Engagement Rating Inventory, which is applied to video recordings of the Communication Play Protocol.
ASD Symptoms - secondary measure148 m, 60 m; 45 minutesAutism Diagnostic Observation Schedule, Second Edition (ADOS-2)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026